Close

Medicago to develop new VLP vaccine candidate for rabies

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Incorporation of Antimicrobial Coatings in Pharmaceuticals

In the very rapidly evolving pharmaceutical spectrum, the safeguarding...

Asia’s CROs VCs: Blurring Service Provider & Investor Roles

In a time characterized by accelerated innovation and ever-more...

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

Asia’s Bio Sovereignty: Nations Reclaiming Biologics Control

The biopharmaceutical industry in the Asia-Pacific area has seen...

Medicago, a biotechnology company, has completed initial studies towards the development of a new VLP vaccine candidate for rabies.

The initial studies with rabies VLP vaccine demonstrated that two doses of one or four micrograms induced protective levels of neutralizing antibodies in a mouse model. The company expects to move ahead with GMP process development and a GLP toxicology study in 2012 and a Phase I clinical trial.

Medicago president and CEO Andrew Sheldon said that they see significant potential for our technologies in the development of VLP vaccines and biosimilars. “The rabies virus is a significant problem where current vaccines present challenges to access due to availability and cost, which we believe our VLP vaccine could address,” Sheldon added.

Latest stories

Related stories

Incorporation of Antimicrobial Coatings in Pharmaceuticals

In the very rapidly evolving pharmaceutical spectrum, the safeguarding...

Asia’s CROs VCs: Blurring Service Provider & Investor Roles

In a time characterized by accelerated innovation and ever-more...

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

Asia’s Bio Sovereignty: Nations Reclaiming Biologics Control

The biopharmaceutical industry in the Asia-Pacific area has seen...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back